Investors pony up $476M for the latest round of biotech IPOs to hit the Street
Three biotechs — and a genome sequencing player — have caught the latest tide to the Gold Coast of IPOs, rounding out the first half of 2019 with 23 new drug developers making it on Nasdaq.
Most of these companies filed their IPOs almost simultaneously, though we’re still waiting on word of fellow classmate BridgeBio’s pricing after CEO Neil Kumar set the terms at $14 to $16 a share on Monday in search of a $240 million (or so) windfall. If he’s successful, that would take the one-week haul past the $700 million mark, a fresh sign that investors’ enthusiasm for newly coined public biotechs hasn’t cooled.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.